Term ends Sep 30, 2033 · High confidence
20-year base term ends Sep 30, 2033
Held by Seven Bridges Genomics Inc.
Filed Jul 28, 2015 as application 14/811,057 · Granted Jul 12, 2016
Base term, 20 years from filing
Today
2013
2033
Clock starts
Sep 30, 2013
Sep 30, 2013
Term ends
Sep 30, 2033
Sep 30, 2033
Granted
Jul 12, 2016
Jul 12, 2016
base term
fee events
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,116,866, to Sep 30, 2033. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 30, 2013, when application 14/041,850, the earliest non-provisional in its chain, was filed (this one was filed Jul 28, 2015) | Sep 30, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,116,866) | resolves to Sep 30, 2033, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 30, 2033 | High confidence |
This family
| US 9,116,866 | In force Sep 2033 | Sep 2033 |
| Application PCT/US2014/058328 | PCT application no patent term | no patent term |
| US 9,390,226 | this patent Sep 2033 | Sep 2033 |
| US 9,904,763 | In force no later than Sep 2033 | no later than Sep 2033 |
| US 10,325,675 | In force Sep 2033 | Sep 2033 |
| US 11,488,688 | In force May 2035 | May 2035 |
| US 11,837,328 | In force no later than Sep 2033 | no later than Sep 2033 |
| US 12,106,826 | In force Sep 2033 | Sep 2033 |
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 25, 2015 Reel 37139, frame 805 | Kural, Deniz | Seven Bridges Genomics Inc. | Assignment of Assignor's Interest |
| Oct 11, 2017 Reel 44174, frame 113 | Seven Bridges Genomics Inc. | Brown Rudnick | Notice of Attorney's Lien |
| Oct 17, 2017 Reel 44305, frame 871 | Seven Bridges Genomics Inc. | Mjolk Holding B.V. | Security Interest |
| Apr 12, 2018 Reel 45928, frame 13 | Mjolk Holding B.V. | Seven Bridges Genomics Inc. | Release of Security Interest |
| Sep 13, 2018 Reel 46943, frame 683 | Brown Rudnick LLP | Seven Bridges Genomics Inc. | Termination and Release of Notice of Attorney's Lien |
| Mar 30, 2022 Reel 59554, frame 165 | Seven Bridges Genomics Inc. | Imperial Financial Services B.V. | Security Interest |
| May 24, 2022 Reel 60173, frame 792 | Imperial Financial Services B.V. | Seven Bridges Genomics Inc. | Release of Security Interest |
| May 24, 2022 Reel 60173, frame 803 | Seven Bridges Genomics Inc. | Imperial Financial Services B.V. | Security Interest |
| Aug 2, 2022 Reel 61055, frame 78 | Imperial Financial Services B.V. | Seven Bridges Genomics Inc. | Release of Security Interest |
| Aug 4, 2022 Reel 61084, frame 786 | Pieriandx, Inc.; Seven Bridges Genomics Inc. | Orbimed Royalty & Credit Opportunities III, LP | Security Interest |
| Oct 9, 2026 reel/frame not recorded | Orbimed Royalty & Credit Opportunities III, LP | Pieriandx, Inc. | Release of Security Interest |
| Oct 9, 2026 reel/frame not recorded | Orbimed Royalty & Credit Opportunities III, LP | Seven Bridges Genomics Inc. | Release of Security Interest |
| Oct 9, 2026 Reel 76676, frame 119 | Orbimed Royalty & Credit Opportunities III, LP | Pieriandx, Inc.; Seven Bridges Genomics Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Sep 2033
Term ends Sep 30, 2033. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 9,116,866, ends no earlier than this term, so it caps nothing.
Citations
81
later US patents cite this one
That is top 5% of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.